Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Hyaluronidase is an enzyme used to improve the absorption and dispersion of parenterally administered fluids, drugs, and contrast agents. The action of hyaluronidase was first described in 1936, and named in 1939.
- Mechanism
- Curator reviewed · 5 references
Hyaluronidase cleaves hyaluronic acid at the glucosaminidic bond between C1 of glucosamine and C4 of glucuronic acid. Hyaluronic acid is a key component of the extracellular matrix. Injection of hyaluronidase with other fluids, drugs, or radiopaque agents improves the ability of these other compounds to permeate the extracellular space more easily.
- Primary indication
- Hyaluronidase is indicated for subcutaneous fluid administration for hydration, and increasing resorption of radiopaque agents in subcutaneous urography.Curator reviewed · 3 structured indications
- First approval
- Canada, 1954 · United States, 2004
- Also known as
- Hyaluronidase (bovine) · Hyaluronidase bovine · Hyaluronidase, bovine · Hyaluronoglucosaminidase
- Brand names
- Amphadase
Resolves to
What you can answer from here — as of January 09, 2026
Which drugs share a target with Hyaluronidase, and which of those have an active Phase 3 trial?